Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Jul;71(7):4962–4970. doi: 10.1128/jvi.71.7.4962-4970.1997

Biochemical characterizations of two temperature-sensitive and attenuated strains of respiratory syncytial virus subgroup B.

J H Broughan 1, V B Randolph 1, J M Tatem 1
PMCID: PMC191727  PMID: 9188559

Abstract

Cold-adapted, temperature-sensitive (ts), attenuated strains of respiratory syncytial virus have been developed from a B subgroup clinical isolate for potential use as vaccine candidates. The replication of two B subgroup ts mutant viruses (2B33F and 2B20L) at the permissive and nonpermissive temperatures have been compared with that of the parental 2B virus to establish differences that may account for their ts and/or attenuated phenotypes. We have shown that the ts restriction at 39 degrees C in the replication of the two mutant viruses in tissue culture occurs at a step after virus adsorption but before or including initiation of virus-specific mRNA transcription. At the permissive temperature of 32 degrees C a 12- to 24-h delay in the accumulation of mRNA for both mutant viruses in comparison to that of the parental 2B virus was exhibited. This effect was mirrored by equivalent delays in viral protein synthesis and production of infectious virus. By 36 h postinfection both mutants had produced levels of viral mRNA, protein, and infectious virus that were similar to those of the parent virus at 32 degrees C. ts+ revertant viruses derived from both mutants have also reverted in their viral mRNA, protein, and infectious virus production kinetics at 32 degrees C to rates more like those exhibited by the parental 2B virus. This suggests a positive correlation between the ts step in the replication of the mutant viruses and the initial delay in mRNA production that occurs at the permissive temperature.

Full Text

The Full Text of this article is available as a PDF (705.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouchard M. J., Lam D. H., Racaniello V. R. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol. 1995 Aug;69(8):4972–4978. doi: 10.1128/jvi.69.8.4972-4978.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Collins P. L., Hill M. G., Camargo E., Grosfeld H., Chanock R. M., Murphy B. R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11563–11567. doi: 10.1073/pnas.92.25.11563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collins P. L., Mottet G. Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus. J Gen Virol. 1993 Jul;74(Pt 7):1445–1450. doi: 10.1099/0022-1317-74-7-1445. [DOI] [PubMed] [Google Scholar]
  4. Crowe J. E., Jr, Bui P. T., Davis A. R., Chanock R. M., Murphy B. R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 1994 Jul;12(9):783–790. doi: 10.1016/0264-410x(94)90286-0. [DOI] [PubMed] [Google Scholar]
  5. Crowe J. E., Jr, Bui P. T., London W. T., Davis A. R., Hung P. P., Chanock R. M., Murphy B. R. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 1994 Jun;12(8):691–699. doi: 10.1016/0264-410x(94)90218-6. [DOI] [PubMed] [Google Scholar]
  6. Heminway B. R., Yu Y., Tanaka Y., Perrine K. G., Gustafson E., Bernstein J. M., Galinski M. S. Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology. 1994 May 1;200(2):801–805. doi: 10.1006/viro.1994.1245. [DOI] [PubMed] [Google Scholar]
  7. Hsu K. H., Crowe J. E., Jr, Lubeck M. D., Davis A. R., Hung P. P., Chanock R. M., Murphy B. R. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Vaccine. 1995 Apr;13(5):509–515. doi: 10.1016/0264-410x(94)00002-5. [DOI] [PubMed] [Google Scholar]
  8. Johnson P. R., Jr, Olmsted R. A., Prince G. A., Murphy B. R., Alling D. W., Walsh E. E., Collins P. L. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol. 1987 Oct;61(10):3163–3166. doi: 10.1128/jvi.61.10.3163-3166.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Luo G., Bergmann M., Garcia-Sastre A., Palese P. Mechanism of attenuation of a chimeric influenza A/B transfectant virus. J Virol. 1992 Aug;66(8):4679–4685. doi: 10.1128/jvi.66.8.4679-4685.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Maassab H. F., DeBorde D. C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine. 1985 Dec;3(5):355–369. doi: 10.1016/0264-410x(85)90124-0. [DOI] [PubMed] [Google Scholar]
  11. Murphy B. R., Hall S. L., Kulkarni A. B., Crowe J. E., Jr, Collins P. L., Connors M., Karron R. A., Chanock R. M. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994 Apr;32(1):13–36. doi: 10.1016/0168-1702(94)90059-0. [DOI] [PubMed] [Google Scholar]
  12. Paradiso P. R., Hu B., Hildreth S., Martin A., Arumugham R. Antigenic structure of the fusion glycoprotein of respiratory syncytial virus. Adv Exp Med Biol. 1989;251:273–278. doi: 10.1007/978-1-4757-2046-4_25. [DOI] [PubMed] [Google Scholar]
  13. Pringle C. R., Filipiuk A. H., Robinson B. S., Watt P. J., Higgins P., Tyrrell D. A. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine. 1993;11(4):473–478. doi: 10.1016/0264-410x(93)90290-e. [DOI] [PubMed] [Google Scholar]
  14. Randolph V. B., Kandis M., Stemler-Higgins P., Kennelly M. S., McMullen Y. M., Speelman D. J., Weeks-Levy C. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res. 1994 Sep;33(3):241–259. doi: 10.1016/0168-1702(94)90106-6. [DOI] [PubMed] [Google Scholar]
  15. Ray R., Galinski M. S., Heminway B. R., Meyer K., Newman F. K., Belshe R. B. Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene. J Virol. 1996 Jan;70(1):580–584. doi: 10.1128/jvi.70.1.580-584.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ray R., Meyer K., Newman F. K., Belshe R. B. Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain. J Virol. 1995 Mar;69(3):1959–1963. doi: 10.1128/jvi.69.3.1959-1963.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Richman D. D., Murphy B. R. The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev Infect Dis. 1979 May-Jun;1(3):413–433. doi: 10.1093/clinids/1.3.413. [DOI] [PubMed] [Google Scholar]
  18. Stott E. J., Taylor G., Ball L. A., Anderson K., Young K. K., King A. M., Wertz G. W. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol. 1987 Dec;61(12):3855–3861. doi: 10.1128/jvi.61.12.3855-3861.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Subbarao E. K., Park E. J., Lawson C. M., Chen A. Y., Murphy B. R. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J Virol. 1995 Oct;69(10):5969–5977. doi: 10.1128/jvi.69.10.5969-5977.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Walsh E. E., Hall C. B., Briselli M., Brandriss M. W., Schlesinger J. J. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis. 1987 Jun;155(6):1198–1204. doi: 10.1093/infdis/155.6.1198. [DOI] [PubMed] [Google Scholar]
  21. Walsh E. E., Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol. 1983 Jul;47(1):171–177. doi: 10.1128/jvi.47.1.171-177.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wertz G. W., Whelan S., LeGrone A., Ball L. A. Extent of terminal complementarity modulates the balance between transcription and replication of vesicular stomatitis virus RNA. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8587–8591. doi: 10.1073/pnas.91.18.8587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yu Q., Hardy R. W., Wertz G. W. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol. 1995 Apr;69(4):2412–2419. doi: 10.1128/jvi.69.4.2412-2419.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zheng H., Peret T. C., Randolph V. B., Crowley J. C., Anderson L. J. Strain-specific reverse transcriptase PCR assay: means to distinguish candidate vaccine from wild-type strains of respiratory syncytial virus. J Clin Microbiol. 1996 Feb;34(2):334–337. doi: 10.1128/jcm.34.2.334-337.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES